BridgeBio Pharma, Inc. (NASDAQ:BBIO) released topline results from the Phase 1/2 open-label ADventure study of BBP-631, an ...

After hours: September 20 at 5:44 PM EDT Loading Chart for AGIO ...

Increased endogenous cortisol production was achieved in all patients at higher doses. A maximum change from baseline post-ACTH stimulation test of 4.7 µg/dL and 6.6 µg/dL was observed at the two ...

Inborn errors of steroidogenesis associated with congenital adrenal hyperplasia are discussed, with a particular focus on the pathophysiology and clinical features of 21-hydroxylase deficiency. The ...

The findings highlight the essential role of AGPs and other cell wall components in maintaining fruit quality. The study ...

Parkinson's disease (PD) is a debilitating movement disorder that affects millions of individuals worldwide, especially older ...

PTC Therapeutics, Inc. got a dose-dependent lowering of mutant Huntingtin protein in both the blood and CSF of HD patients ...

Neurotransmitters are key for synaptic transmission at axon terminals, but their transport modalities remain debated. This ...

California, USA-based biotech BridgeBio Pharma saw its shares dip 4% to $29.60 yesterday on disappointing clinical results ...

BridgeBio Pharma, Inc. has released the topline results from the phase 1/2 open-label adventure study investigating BBP-631, an investigational gene therapy for congenital adrenal hyperplasia (CAH).